Lyra Therapeutics, Inc.

NasdaqGM:LYRA Stock Report

Market Cap: US$11.8m

Lyra Therapeutics Valuation

Is LYRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LYRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LYRA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYRA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LYRA?

Key metric: As LYRA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LYRA. This is calculated by dividing LYRA's market cap by their current revenue.
What is LYRA's PS Ratio?
PS Ratio8x
SalesUS$1.47m
Market CapUS$11.78m

Price to Sales Ratio vs Peers

How does LYRA's PS Ratio compare to its peers?

The above table shows the PS ratio for LYRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.2x
JAGX Jaguar Health
1x34.8%US$10.9m
EVOK Evoke Pharma
1.2x59.5%US$10.5m
MRNS Marinus Pharmaceuticals
0.4x35.2%US$12.7m
PULM Pulmatrix
2.2xn/aUS$21.9m
LYRA Lyra Therapeutics
8x61.6%US$11.8m

Price-To-Sales vs Peers: LYRA is expensive based on its Price-To-Sales Ratio (8x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does LYRA's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

69 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x0.02%US$3.75b
PRGO Perrigo
0.8x3.4%US$3.51b
BHC Bausch Health Companies
0.3x1.5%US$2.75b
AMRX Amneal Pharmaceuticals
0.9x5.6%US$2.41b
LYRA 8.0xIndustry Avg. 3.0xNo. of Companies69PS03.67.210.814.418+
69 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LYRA is expensive based on its Price-To-Sales Ratio (8x) compared to the US Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is LYRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LYRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LYRA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LYRA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.18
US$1.25
+594.4%
60.0%US$2.00US$0.50n/a2
Dec ’25US$0.21
US$1.25
+503.3%
60.0%US$2.00US$0.50n/a2
Nov ’25US$0.26
US$1.25
+382.8%
60.0%US$2.00US$0.50n/a2
Oct ’25US$0.26
US$1.25
+382.6%
60.0%US$2.00US$0.50n/a2
Sep ’25US$0.32
US$4.50
+1,298.8%
103.0%US$11.00US$0.50n/a3
Aug ’25US$0.31
US$4.50
+1,369.1%
103.0%US$11.00US$0.50n/a3
Jul ’25US$0.30
US$4.50
+1,415.7%
103.0%US$11.00US$0.50n/a3
Jun ’25US$0.33
US$4.50
+1,272.0%
103.0%US$11.00US$0.50n/a3
May ’25US$5.25
US$11.60
+121.0%
16.0%US$15.00US$10.00n/a5
Apr ’25US$6.25
US$12.00
+92.0%
13.9%US$15.00US$10.00n/a5
Mar ’25US$5.69
US$12.20
+114.4%
13.1%US$15.00US$10.00n/a5
Feb ’25US$4.59
US$11.80
+157.1%
18.9%US$15.00US$8.00n/a5
Jan ’25US$5.24
US$11.80
+125.2%
18.9%US$15.00US$8.00n/a5
Dec ’24US$3.62
US$12.33
+240.7%
19.1%US$15.00US$8.00US$0.216
Nov ’24US$2.95
US$12.67
+329.4%
20.7%US$15.00US$8.00US$0.266
Oct ’24US$3.91
US$12.20
+212.0%
21.6%US$15.00US$8.00US$0.265
Sep ’24US$3.49
US$10.60
+203.7%
34.1%US$15.00US$5.00US$0.325
Aug ’24US$3.28
US$10.75
+227.7%
35.7%US$15.00US$6.00US$0.314
Jul ’24US$4.11
US$10.75
+161.6%
35.7%US$15.00US$6.00US$0.304
Jun ’24US$2.70
US$10.75
+298.1%
35.7%US$15.00US$6.00US$0.334
May ’24US$2.59
US$14.00
+440.5%
23.1%US$18.00US$9.00US$5.254
Apr ’24US$2.01
US$15.20
+656.2%
24.8%US$20.00US$9.00US$6.255
Mar ’24US$2.26
US$16.75
+641.2%
14.2%US$20.00US$14.00US$5.694
Feb ’24US$2.90
US$17.75
+512.1%
22.0%US$24.00US$14.00US$4.594
Jan ’24US$3.14
US$17.75
+465.3%
22.0%US$24.00US$14.00US$5.244
Dec ’23US$3.36
US$17.75
+428.3%
22.0%US$24.00US$14.00US$3.624

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 18:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lyra Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Justin ZelinBTIG
null nullBTIG